Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Abstract:
On Thursday, October 2, 2008, Dr. Tamarkin will be a featured speaker from 10:30-12:30 in the medicine and biology track at NanoTx08. His speech will focus on the recent Phase I CYT-6091 cancer patient trial in which the Company's gold nanomedicine was used to deliver a potent, but toxic, anti-cancer therapeutic to solid tumors. Such tumor targeting is best accomplished by avoiding uptake by the immune system and by limiting the biodistribution of the drug to the tumor. CYT-6091 accomplishes this by binding the potent, but toxic molecule TNF to the surface of PEGylated colloidal gold nanoparticles. TNF's toxicity is so severe that its clinical use is limited to isolated limb perfusion (ILP), where 1 mg of TNF followed by doxorubicin results in a 60-85% local response rate. In the completed CYT-6091 Phase I dose escalation clinical trial a similar dose of TNF was injected systemically. The treatment was well-tolerated, showing no dose limiting toxicity, and patient biopsies taken 24-hours after treatment showed gold nanoparticles in patient tumors. Multiple Phase II combination trials are planned.

The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Rockville, MD | Posted on September 30th, 2008

####

About CytImmune Sciences, Inc.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.

Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a patented, semi-synthetic in vitro immune system capable of producing fully-human monoclonal antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to create a separate class of nanomedicines.

For more information, please click here

Contacts:
CytImmune Sciences
9640 Medical Center Drive
Rockville, MD 20850
Phone: (240)-864-2796
Fax: (301) 315-2438

Copyright © CytImmune Sciences, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Shining rings: A new material emits white light when exposed to electricity: New synthetic approach could spark development of other dynamic materials July 24th, 2017

Ultrathin device harvests electricity from human motion July 23rd, 2017

The July 23 close fly-by of asteroid 2017 BS5 is explored in a Q&A with Dr. John S. Lewis, chief scientist at Deep Space Industries July 23rd, 2017

Scientists announce the quest for high-index materials: All-dielectric nanophotonics: The quest for better materials and fabrication techniques July 22nd, 2017

Nanomedicine

Shining rings: A new material emits white light when exposed to electricity: New synthetic approach could spark development of other dynamic materials July 24th, 2017

Scientists announce the quest for high-index materials: All-dielectric nanophotonics: The quest for better materials and fabrication techniques July 22nd, 2017

Probiotics: Novel biosynthetic tool to develop metallic nanoparticles: This research article by Dr. Nida Akhtar et al has been published in Recent Patents on Drug Delivery & Formulation, Volume 11, Issue 1, 2017 July 20th, 2017

Semiliquid chains pulled out of a sea of microparticles July 20th, 2017

Announcements

Shining rings: A new material emits white light when exposed to electricity: New synthetic approach could spark development of other dynamic materials July 24th, 2017

Ultrathin device harvests electricity from human motion July 23rd, 2017

The July 23 close fly-by of asteroid 2017 BS5 is explored in a Q&A with Dr. John S. Lewis, chief scientist at Deep Space Industries July 23rd, 2017

Scientists announce the quest for high-index materials: All-dielectric nanophotonics: The quest for better materials and fabrication techniques July 22nd, 2017

Events/Classes

Nanometrics to Announce Second Quarter Financial Results on August 1, 2017 July 14th, 2017

Nanometrics Introduces SpectraProbe Analysis Software: Advanced software and algorithms enhancing Nanometrics metrology fleet capabilities fab-wide July 13th, 2017

Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project